Login with your work email address to view charts. No credit card required.
| Art Unit: | 1638 — Drug, bio-affecting and body treating compositions |
|---|---|
| Group: | 1630 — Stem cells and cell culture and Nucleic Acid related therapy |
| Classes: |
424 — Drug, bio-affecting and body treating compositions 435 — Chemistry: molecular biology and microbiology 514 — Drug, bio-affecting and body treating compositions 800 — Multicellular living organisms and unmodified parts thereof and related processes 536 — Organic compounds -- part of the class 532-570 series 530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof 436 — Chemistry: analytical and immunological testing 604 — Surgery 506 — Combinatorial chemistry technology: method, library, apparatus 494 — Imperforate bowl: centrifugal separators |
| Phone: | (571) 272-2915 |
| Email: | michael.burkhart@uspto.gov |
| Location: | VA 22314 |
| Title: | Pat Examnr Micrbiolgy |
| Service: | 22 years |
| Grade: | GS-14 |
| 3-Year Grant rate: | 62% over 296 cases |
|---|---|
| Difficulty: | Harder |
| Difficulty Percentile: | 70th
|
With Examiner Burkhart, you have a 62% chance of getting an issued patent by 3 years after the first office action. Examiner Burkhart is a harder examiner and in the 70th percentile across all examiners (with 100th percentile most difficult).
Below is the grant rate timeline for Examiner Burkhart, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.
Examiner Burkhart's grant rate is higher than that of Art Unit 1638 and lower than that of the USPTO.
| Average Office Actions Per Grant | |
|---|---|
| Examiner Burkhart | 1.7 |
| Art Unit 1638 | 2.1 |
Examiner Burkhart has granted 174 of 283 cases without any applicant-requested interviews for a grant rate of 61%.
Examiner Burkhart has granted 10 of 13 cases with at least one applicant-requested interview for a grant rate of 77%.
With Examiner Burkhart, conducting an interview increases your chance of getting a patent granted by 26%.
| Number | Title | OA Rejections | Status | IFW |
|---|---|---|---|---|
| 19070308 | Method And Apparatus For Producing Car T Cells | Rejection information available with a Premium Stats subscription. See our pricing. | Patented | View |
| 17997042 | Structure, Method For Producing Same, Adsorbent In Which Same Is Used, And Method For Purifying Bioparticles | Abandoned | View | |
| 17309209 | Methods For The Simultaneous Expansion Of Multiple Immune Cell Types, Related Compositions And Uses Of Same In Cancer Immunotherapy | Patented | View | |
| 17285440 | Programmable Dna Base Editing By Nme2cas9-Deaminase Fusion Proteins | Patented | View | |
| 18149611 | Compositions And Methods For Treating Idiopathic Overactive Bladder Syndrome And Detrusor Overactivity | Abandoned | View | |
| 17908712 | Method For Selecting Aptamers With High Target Specificity In A Microfluidic Device Platform For Co-Culture Of Multiple Tissues | Patented | View | |
| 17938787 | Regulated Synthetic Gene Expression Systems | Patented | View | |
| 17126833 | Methods And Compositions For Delivering Mrna Coded Antibodies | Patented | View | |
| 17582682 | Arenavirus Particles As Cancer Vaccines | Abandoned | View | |
| 17936059 | Compositions And Methods For Making Antibodies Based On Use Of Expression-Enhancing Loci | Patented | View | |
| 17559967 | Chimeric Antigen Receptor Dendritic Cell (Car-Dc) For Treatment Of Cancer | Abandoned | View | |
| 17365912 | Ligand Matched Transcription Control, Control Devices, And Solute Carriers | Abandoned | View | |
| 16988697 | Cancer Treatment Methods Using Thermotherapy And/or Enhanced Immunotherapy | Abandoned | View | |
| 18054350 | Compositions And Methods For Making Antibodies Based On Use Of An Expression-Enhancing Locus | Patented | View | |
| 17037804 | Treatment Of Myotonic Dystrophy | Patented | View | |
| 16470924 | T Cell-Targeted T Cells | Abandoned | View | |
| 17278847 | Gene Therapy For Treating Propionic Acidemia | Patented | View | |
| 16510818 | Meningeal Repair Using Human Umbilical Cord Patches | Patented | View | |
| 19171465 | Compositions And Methods For The Treatment Of Ven/aza Resistant Acute Myeloid Leukemia | Patented | View | |
| 17701488 | Vector System For Expressing Regulatory Rna | Patented | View | |
| 19043304 | Pseudotyped Viral Particles, Compositions Comprising The Same, And Uses Thereof | Patented | View | |
| 17571325 | Cd19-Directed Chimeric Antigen Receptors And Uses Thereof In Immunotherapy | Patented | View | |
| 17226961 | Methods And Compositions For Editing Rnas | Abandoned | View | |
| 17659598 | Vectors And Methods For Regenerative Therapy | Abandoned | View | |
| 16934606 | Elimination Of Cd19-Positive Lymphoid Malignancies By Cd19-Car Expressing Nk Cells | Patented | View | |
| 18895296 | Immune Cells Defective For Suv39h1 | Patented | View | |
| 17741024 | Vectors For The Treatment Of Friedreich's Ataxia | Patented | View | |
| 17295588 | Methods And Compositions For Treating Osteoarthritis | Patented | View | |
| 17115565 | Chimeric Antigen Receptor And Methods Of Use Thereof | Patented | View | |
| 17292343 | Gene Therapy Employing Genome Editing With Single Aav Vector | Abandoned | View | |
| 17792713 | Preparation Method And System For Recombinant Adeno-Associated Virus, And Recombinant Bacmid | Patented | View | |
| 16616099 | Use Of The Il-15/il-15ra Complex In The Generation Of Antigen-Specific T Cells For Adoptive Immunotherapy | Patented | View | |
| 17893052 | New Oncolytic Virus Platform To Treat Cancers With Myxoma Virus | Patented | View | |
| 17956257 | Phagemid Vector | Patented | View | |
| 17659007 | Methods And Compositions For Genetically Modifying Lymphocytes To Express Polypeptides Comprising The Intracellular Domain Of Cd79a And Cd79b | Patented | View | |
| 17374147 | Recombinant Virus Products And Methods For Inhibition Of Expression Of Myotilin | Patented | View | |
| 18157052 | Methods And Compositions For Genomic Integration | Patented | View | |
| 18158173 | Enhanced Virus-Like Particles And Methods Of Use Thereof For Delivery To Cells | Patented | View | |
| 17066134 | Spherical Nucleic Acid-Based Constructs As Immunostimulatory Agents For Prophylactic And Therapeutic Use | Abandoned | View | |
| 17823186 | Humanized Il-4 And Il-4ra Animals | Patented | View | |
| 18068376 | Methods And Compositions For Modified Factor Ix Fusion Proteins | Patented | View | |
| 18066175 | Methods To Produce Rod-Derived Cone Viability Factor (Rdcvf) | Abandoned | View | |
| 18773146 | Composition For Regulating Production Of Proteins | Patented | View | |
| 16767497 | Reprogrammed T Cell-Like Nk Cells | Patented | View | |
| 17871383 | Methods And Compositions For Generating Pacemaker Cells | Abandoned | View | |
| 17879559 | Microorganisms Programmed To Produce Immune Modulators And Anti-Cancer Therapeutics In Tumor Cells | Abandoned | View | |
| 16744296 | Method For Utilizing Engineered Dendritic Cells To Induce Gut-Homing Regulatory T Cells And Treat Gut Inflammation | Patented | View | |
| 17862666 | Rapid Assay For Detection Of Sars-Cov-2 Antibodies | Patented | View | |
| 17938501 | Modified Monocytes/macrophage Expressing Chimeric Antigen Receptors And Uses Thereof | Abandoned | View | |
| 17275832 | Methods And Compositions For Treating Cancer Using Mrna Therapeutics | Abandoned | View |
Subscribe to Premium Examiner Statistics for unlimited access for your law firm.
Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.